Gosta Labs Completes €7.5M Seed to Scale its AI Operating System for Oncology Professionals Worldwide
Helsinki, November 27, 2025 – Gosta Labs, a Helsinki-based healthtech company founded by the ex-Kaiku Health founders, has closed a €7.5 million seed round to scale its AI operating system for complex medical specialties. The round was led by Voima Ventures, with participation from COR Group, the Aho family, and both existing and new investors, including Reaktor and a group of notable angel investors. This follows a €1.7 million pre-seed round in 2024 and brings the company’s total funding to nearly €10 million.
The growing complexity of cancer care requires modern AI support
Cancer care is becoming increasingly complex. By 2050, more than 35 million new cancer cases are expected to be diagnosed across over 100 different types of cancer [1][2]. Meanwhile, clinicians spend several hours a day on administrative work within fragmented systems and unstructured clinical data, while multidisciplinary teams must make fast, high-stakes decisions regarding an ever-growing number of personalised treatment options.
Gosta Labs addresses these challenges with an oncology-focused AI operating system that transforms every patient visit into high-quality structured data in real time. The system summarizes and visualizes patient journeys, automates clinical documentation, and captures structured clinical data relevant to patient care. It also improves quality of care by assessing key clinical parameters for each treatment pathway and automatically linking decisions to international guidelines. This enables oncologists to deliver faster and more consistent care.
Gosta Labs’ AI operating system is already in use with leading healthcare providers in Finland, Switzerland, the Baltics, and Australia.
First real-world data indicate improvements in oncology workflows
The first real-world results from the Gosta AI Operating System were presented at the ESMO 2025 Congress, a leading global oncology conference. Results suggest that the oncology-focused system generates high-quality oncology consultation notes in real time, structured according to institutional standards. It also automatically classifies Performance Status and CTCAE toxicity grades. Oncologists were able to complete follow-up visit documentation in a median time of under two minutes, significantly reducing their documentation burden and enabling them to spend more time with patients.
”This technology is already reshaping our clinical workflows. The ability to produce structured, accurate notes instantly and classify key clinical parameters automatically frees oncologists to spend their time where it matters most — with their patients. In practice, this has already cut documentation time by over two-thirds for each patient visit at our cancer center”, says Dr. Razvan Popescu, Medical Director at Tumor Center Aargau and the lead investigator in the study.
Founders with a proven track record in digital health
Founded in 2023 by Lauri Sippola and Henri Viertolahti, who previously founded Kaiku Health (acquired by Elekta in 2020), Gosta Labs’ roots are in a proven track record of building and scaling regulated digital health worldwide.
The company’s team combines AI scientists with experienced oncology and medtech leaders, including Chief Medical Officer Dr. Lionel Hadjadjeba and Chief Operating Officer Reetta Arokoski, both of whom bring decades of experience in scaling cancer-care technologies internationally.
“Gosta Labs’ key team members combine proven startup execution, deep domain expertise and top notch AI capabilities. They’ve done it before and know what good looks like, which is an essential for any startup team,” said Jussi Sainiemi, Partner at Voima Ventures. “There’s a lot of hype around AI but Gosta delivers the value it promises and customers love the product.”
“We started Gosta Labs to bring AI to support extremely complex medical specialties like oncology, to give care teams back time and headspace for their patients by taking on the documentation work that drains their day,” said Lauri Sippola, CEO and Co Founder of Gosta Labs. “This funding helps us bring our trusted AI assistant to oncology teams around the world and deepen our medical device grade product and AI foundation, so every patient encounter can be safer, more personal, and less burdened by administration.”
[1]Source of data: IARC. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024).
[2] Source of data: National Cancer Institute. What is Cancer? (2021).
***
Additional information:
Lauri Sippola
CEO & Co-Founder, Gosta Labs
lauri@gostalabs.com
+358 40 744 7481
Emma Kettunen
Global Marketing & Communications, Gosta Labs
emma@gostalabs.com
+358 44 056 4114
About Gosta Labs
Gosta Labs is a healthtech company redefining healthcare with artificial intelligence. The company is developing an AI operating system for complex medical specialties, like oncology, enabling more efficient, precise, and personalized care across the entire patient journey. Founded in 2023 by the former founders of Kaiku Health (acquired by Elekta in 2020), Gosta Labs partners with leading healthcare providers in Finland, Switzerland, the Baltics, and Australia. The company is backed by investors including Voima Ventures, COR Group, the Aho family, Reaktor and a group of notable angel investors.
